Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study

Leukemia

Volumn 10, Issue 11, 1996, Pages 1741-1750

  Sonneveld, P ^a   Marie, J P ^b   Huisman, C ^a   Vekhoff, A ^b   Schoester, M ^a   Faussat, A M ^b   Van Kapel, J ^a   Groenewegen, A ^c   Charnick, S ^c   Zittoun, R ^b   Lowenberg B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HÔTEL DIEU   (France)

^c Sandoz Pharma Ltd   (Switzerland)

Author keywords

Doxorubicin; Multidrug resistance; Multiple myeloma; SDZ PSC 833

Indexed keywords

CD38 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; DOXORUBICINOL; GLYCOPROTEIN P; MELPHALAN; RHODAMINE; VALSPODAR; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPONATREMIA; HYPOPLASIA; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEUROPATHY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 10344248680     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alexanian R and Dimopoulos M. The treatment of multiple myeloma. New Engl J Med 1994; 330: 484-498.
2. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 1995; 32: 31-44.
3. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913-917.
4. Gottesman MM, Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem 1988; 263: 12163-12166.
5. Fojo AT, Ueda K, Salmon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
6. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump in human hematopoietic stem cells. Cell 1991; 66: 85-94.
7. Beck WT. Multidrug resistance and its circumvention. Eur J Cancer 1990; 26: 513-527.
8. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek A, Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin A. Int J Cancer 1990; 45: 263-268.
9. Pearce HL, Winter MA, Beck WT. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv Enz Reg 1990; 30: 357-373.
10. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990; 82: 1133-1140.
11. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug-resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
12. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215-2222.
13. Grogan TM, Spier CM, Salmon SE, Metzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-495.
14. Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haematol 1993; 83: 63-67.
15. Cornelissen J, Sonneveld P, Schoester M, Nieuwenhuis HK, Dekker AW, Lokhorst HM. MDR-1 expression and response to vincristine, doxorubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994; 12: 115-120.
16. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-424.
17. Dalton WS, Grogan T, Rybski J, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical detection and quantitation of P-glycoprotein in drug resistant human multiple myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73: 747-752.
18. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma. J Clin Oncol 1994; 12: 1584-1591.
19. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991; 77: 348-354.
20. Salmon SE, Dalton WS, Crogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44-50.
21. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solba G, Suciu S, Zittoun R, Löwenberg B, Nooter K. Modulation of multidrug resistance by cyclosporin. Lancet 1992; 340: 255-259.
22. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226-4233.
23. Erlichman C, Moore MJ, De Angelis C, Goodman P, Manzo J. The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer. Anticancer Drugs 1994; 5 (Suppl. 1): 44.
24. Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker: New York, 1982.
25. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, Schuurhuis GJ. Quality control of multidrug resistance assays in adult leukemia: correlation between assays for P-Glycoprotein expression and activity. Blood 1996; 87: 4809-4816.
26. Hausdorff J, Fisher GA, Halsey J, Sikic BI. A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance. Proc ASCO 1995; 181 a.
27. Fisher GA, Hausdorff J, Lum BL, Pearce T, Halsey J, Sikic BI. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc ASCO 1995; 181a.
28. Boole DJ, Dennis IF, Twentyman PE. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-518.
29. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994; 12: 835-842.
30. List AF, Spier C, Greer J, Wolff G, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-1660.
31. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland HD, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
32. R) in combination with SDZ PSC 833, a potent modilator of multidrug resistance (MDR). Anti-Cancer Drugs 1994; 5 (Suppl. 1): 43.
33. Weinstein R, Bellamy W. Functional diversity in the multidrug resistance gene family. Lab Invest 1994; 71: 617-620.
34. Burger HM, Nooter K, Sonneveld P, van Wingerden KE, Zaman GJR, Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukemia. Br J Haematol 1994; 88: 348-356.
35. Linsenmeyer ME, Jefferson S, Wolf M. Levels of expression of the mdr1 gene and glutathione-S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992; 65: 471-475.